FarmaMondo SA and Rev-Pharma, a US bases pharmaceutical company, announce a Global Early Access program targeted to facilitate access to therapy for patient group suffering from an Ultra Rare dermatology disease.
Curefini® dermal ointment is intended for improving the Dermatology Quality of Life (DQL) of patients with various skin disorders.
It has been successfully relieved symptoms of mild and severe skin conditions.
Curefini® dermal ointment works by temporarily protecting injured or exposed skin or mucous membrane surfaces from harmful or annoying stimuli and may provide relief to such surfaces.
Farmamondo will provide exclusive access to this medication for patients globally (excluding US, Peru, Brazil, Argentina and Uruguay where product is registered or under registration) via a model of early access whereas product will be stored in our facility and dispatched according to the demand.
Healthcare providers can obtain details about
Curefini® dermal ointment Access Program by contacting FarmaMondo’s Program
Manager at +41 91 697 6390, or emailing firstname.lastname@example.org.
About Rev Pharma: Rev Pharma is a US based Pharmaceutical company dedicated for the research and development of therapies to support patients with Epidermolysis bullosa (EB) - a group of inherited connective tissue diseases that cause blisters in the skin and mucosal membranes, with an incidence of 20 per million newborns in the United States.
About Farmamondo: Farmamondo is a Swiss-based pharmaceutical company with a focus on providing patient access to their unmet medical need via Early-access, Named-patient and Compassionate-use programs. Our global footprint includes commercial operations in more than 50 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America